Medical Therapies for the Treatment of Osteoarthritis in the Horse – 20 years later….

Overview

• This article reviews the advancements in medical treatments for osteoarthritis (OA) in horses over the past 20 years, highlighting the shift from symptom management to disease-modifying therapies.

Introduction to Osteoarthritis in Horses

• Osteoarthritis (OA) is a chronic, degenerative joint disease causing irreversible damage to the cartilage and overall joint structure.
• OA results from a catabolic cascade, leading to joint deterioration, pain, and loss of function.
• Managing OA effectively is crucial for maintaining equine health and performance.

Historical Context: The 2006 Narrative Review

• The 2006 review by Goodrich and Nixon summarized then-available medical treatments for equine OA.
• At that time, treatment mainly focused on managing OA symptoms rather than altering the disease progression.
• Conventional therapies included anti-inflammatory drugs, joint supplements, and physical therapy strategies.

Progress in Therapeutic Options Over 20 Years

• The number and variety of medical treatments for equine OA have significantly increased.
• Conventional therapies are still in use but have been refined for improved efficacy and precision.
• There is ongoing research to optimize existing treatments and validate their clinical benefits in horses.

Emergence and Development of Orthobiologic Therapies

• Orthobiologic therapies refer to treatments derived from biological substances to promote tissue healing and regeneration.
• Since their introduction, these therapies have evolved extensively, including both allogenic (from donors) and autologous (from the same individual) products.
• Examples include platelet-rich plasma (PRP), mesenchymal stem cells (MSCs), and other cell-based products designed to repair cartilage or reduce inflammation.

Advancements in Cellular-Based Therapies

• Cellular therapies have gained importance, focusing on stimulating the body’s own repair mechanisms within joints affected by OA.
• Improvements in isolation, culture, and delivery methods of therapeutic cells have enhanced these interventions’ effectiveness.
• Such therapies aim to not only alleviate symptoms but also to modify or slow the disease course by encouraging tissue regeneration.

Shift from Symptom Management to Disease Modification

• Earlier treatments targeted pain relief and inflammation control, aiming to improve quality of life without impacting the underlying disease process.
• Recent therapeutic advances focus on modifying the OA pathology, trying to halt or reverse joint degradation.
• This represents a fundamental change in equine OA management, with more emphasis on long-term joint health.

Current Evidence-Based Recommendations

• The review integrates the latest research findings to guide veterinarians on selecting appropriate therapeutic agents for OA in horses.
• It highlights the importance of evidence-based decision making, considering efficacy, safety, and practical application of various treatments.
• The guide helps clinicians balance traditional and novel treatments based on scientific validation and clinical outcomes.

Conclusion

• The last 20 years have seen substantial advancements in the medical treatment of equine OA.
• With a broader and more sophisticated arsenal of therapies, clinicians can better address the complex nature of OA.
• This evolution improves the prospects for horses suffering from OA, aiming for enhanced joint health and sustained performance capabilities.